Prothena Corporation plc

PRTA Healthcare Biotechnology

Prothena Corporation plc’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS grew 84.6% and free cash flow grew 44.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.42 0.01 −0.12%
Market cap
$432.8M
P/E
0.0×
Fwd P/E
188×
Dividend yield
—
F-score
2/9
Altman Z
−0.24
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 3 2 2

+8 more TTM periods

ROE
(14.39%) (40.30%) (63.62%) (67.63%)
ROA
(12.54%) (35.77%) (55.86%) (59.18%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(15.55%) (48.98%) (88.28%) (96.38%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.17) (1.51) (3.04) (3.50)
Free Cash Flow
(60.80) (81.34) (163.72) (188.22)
Capital Expenditures
(0.75) — (0.14) (0.18)
Other line items
Cash ROIC
(10.57%) (12.67%) (27.84%) (30.08%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
(0.01) 0.42 0.22 0.17
Research and Development Expense of Revenue
119.11% 166.84% 1,392.52% 1,446.11%
Selling, General and Administrative Expense of Revenue
90.68% 93.99% 613.30% 539.57%
Share Based Compensation of Revenue
53.30% 58.00% 388.68% 348.60%
Operating CF/Net income
1.37 0.54 0.67 0.67
Depreciation/Fixed assets
1.50 1.89 1.73 1.49
Capex/Depreciation
(0.20) 0.00 (0.04) (0.05)
Revenue per Share
1.05 1.08 0.18 0.22
Operating CF per Share
(1.15) (1.51) (3.04) (3.49)
Capex per Share
(0.01) 0.00 0.00 0.00
Capex to Sales
0.01 0.00 0.01 0.02

Fold the line items

Columns are period end dates